CA3069821A1 - Encapsulated polynucleotides and methods of use - Google Patents

Encapsulated polynucleotides and methods of use Download PDF

Info

Publication number
CA3069821A1
CA3069821A1 CA3069821A CA3069821A CA3069821A1 CA 3069821 A1 CA3069821 A1 CA 3069821A1 CA 3069821 A CA3069821 A CA 3069821A CA 3069821 A CA3069821 A CA 3069821A CA 3069821 A1 CA3069821 A1 CA 3069821A1
Authority
CA
Canada
Prior art keywords
mir
recombinant dna
dna molecule
virus
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3069821A
Other languages
English (en)
French (fr)
Inventor
Mitchell H. Finer
Edward Kennedy
Lorena Lerner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elevatebio Technologies Inc
Original Assignee
Oncorus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncorus Inc filed Critical Oncorus Inc
Publication of CA3069821A1 publication Critical patent/CA3069821A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/32043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA3069821A 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use Pending CA3069821A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762532886P 2017-07-14 2017-07-14
US62/532,886 2017-07-14
US201862648651P 2018-03-27 2018-03-27
US62/648,651 2018-03-27
PCT/US2018/042136 WO2019014623A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Publications (1)

Publication Number Publication Date
CA3069821A1 true CA3069821A1 (en) 2019-01-17

Family

ID=65002120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3069821A Pending CA3069821A1 (en) 2017-07-14 2018-07-13 Encapsulated polynucleotides and methods of use

Country Status (13)

Country Link
US (1) US20200224220A1 (https=)
EP (1) EP3652325A4 (https=)
JP (2) JP2020530778A (https=)
KR (1) KR20200036873A (https=)
CN (1) CN111212914A (https=)
AU (1) AU2018301701A1 (https=)
BR (1) BR112020000839A2 (https=)
CA (1) CA3069821A1 (https=)
IL (1) IL271969A (https=)
MX (1) MX2020000495A (https=)
RU (1) RU2020106730A (https=)
SG (1) SG11202000312UA (https=)
WO (1) WO2019014623A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113368261A (zh) * 2021-06-17 2021-09-10 苏州大学 一种非病毒载体及其制备方法与应用
EP4180810A4 (en) * 2020-07-10 2024-12-25 Shanghai Miran Biotech Co., Ltd. FLUORESCENT CROSSLINKED RNASE H MUTANT CONJUGATE, MIRNA COMBINATION AND APPLICATION THEREOF

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018306455A1 (en) 2017-07-26 2020-02-27 Virogin Biotech Canada Ltd Oncolytic viral vectors and uses thereof
TW202545984A (zh) 2017-08-09 2025-12-01 美商生物化學醫療公司 核酸分子及其用途
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
EP3765048B1 (en) * 2018-03-12 2025-08-27 Mayo Foundation for Medical Education and Research Using infectious nucleic acid to treat cancer
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CN113166783B (zh) 2018-10-09 2024-10-11 不列颠哥伦比亚大学 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法
EP3880812A4 (en) * 2018-11-13 2022-09-07 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
EP3906039A4 (en) * 2019-01-04 2023-01-18 Oncorus, Inc. ENCAPSULATED POLYNUCLEOTIDES AND METHODS OF USE
JP2022526094A (ja) * 2019-03-14 2022-05-23 マサチューセッツ インスティテュート オブ テクノロジー 操作された単純ヘルペスウイルス－１（ｈｓｖ－１）ベクターおよびその使用
CN114514323A (zh) * 2019-08-05 2022-05-17 复诺健生物科技加拿大有限公司 遗传修饰的肠病毒载体
CA3157063A1 (en) * 2019-10-10 2021-04-15 Oncorus, Inc. Dual viruses and dual oncolytic viruses and methods of treatment
US20230416308A1 (en) * 2020-05-29 2023-12-28 Oncorus, Inc. Encapsulated rna replicons and methods of use
BR112022025217A2 (pt) * 2020-06-11 2023-01-03 Etherna Immunotherapies Nv Nanopartículas lipídicas
AU2022206676A1 (en) * 2021-01-06 2023-08-24 Elevatebio Technologies, Inc. Encapsulated rna polynucleotides and methods of use
US20250027107A1 (en) 2021-10-18 2025-01-23 Flagship Pioneering Innovations Vii, Llc Dna compositions and related methods
TW202409286A (zh) * 2022-05-20 2024-03-01 加拿大商復諾健生物科技加拿大有限公司 基因組穩定性增強之基因改造腸病毒載體
JP7229412B1 (ja) 2022-06-14 2023-02-27 キユーピー株式会社 脂質ナノ粒子及びその製造方法
CN118634238A (zh) * 2022-06-27 2024-09-13 浙江大学 抗口腔肿瘤药物活性成分及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060026854A (ko) * 2003-05-28 2006-03-24 위스콘신 얼럼나이 리서어치 화운데이션 ＰｏｌⅡ 프로모터 및 리보자임을 갖는 재조합 인플루엔자벡터
WO2005030139A2 (en) * 2003-09-26 2005-04-07 Novartis Ag Seneca valley virus based compositions and methods for treating disease
US7473418B2 (en) * 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
GB0810912D0 (en) * 2008-06-13 2008-07-23 Inst Animal Health Ltd Vector
CA2738472A1 (en) * 2008-09-26 2010-04-22 Tocagen Inc. Gene therapy vectors and cytosine deaminases
CA2782366A1 (en) * 2009-12-16 2011-07-14 Opko Curna, Llc Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1
WO2013083753A2 (en) * 2011-12-07 2013-06-13 Institut Pasteur Identification of a swine parecho-like virus and applications
EP2839015B1 (en) * 2012-04-18 2020-04-29 Ramot at Tel-Aviv University Ltd. Lipidated glycosaminoglycan particles for the delivery of nucleic acids
JP6396891B2 (ja) * 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
US10513711B2 (en) * 2014-08-13 2019-12-24 Dupont Us Holding, Llc Genetic targeting in non-conventional yeast using an RNA-guided endonuclease
EP3307308A2 (en) * 2015-06-10 2018-04-18 Hookipa Biotech AG Hpv vaccines
CN108601802A (zh) * 2015-12-02 2018-09-28 纪念斯隆-凯特林癌症中心 塞尼卡谷病毒（svv）细胞受体靶向的肿瘤治疗

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4180810A4 (en) * 2020-07-10 2024-12-25 Shanghai Miran Biotech Co., Ltd. FLUORESCENT CROSSLINKED RNASE H MUTANT CONJUGATE, MIRNA COMBINATION AND APPLICATION THEREOF
CN113368261A (zh) * 2021-06-17 2021-09-10 苏州大学 一种非病毒载体及其制备方法与应用

Also Published As

Publication number Publication date
BR112020000839A2 (pt) 2020-07-21
US20200224220A1 (en) 2020-07-16
RU2020106730A (ru) 2021-08-16
EP3652325A4 (en) 2021-09-15
EP3652325A1 (en) 2020-05-20
CN111212914A (zh) 2020-05-29
IL271969A (en) 2020-02-27
AU2018301701A1 (en) 2020-02-27
MX2020000495A (es) 2020-08-20
SG11202000312UA (en) 2020-02-27
JP2020530778A (ja) 2020-10-29
KR20200036873A (ko) 2020-04-07
JP2023165916A (ja) 2023-11-17
WO2019014623A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US20200224220A1 (en) Encapsulated polynucleotides and methods of use
US20210403950A1 (en) Encapsulated polynucleotides and methods of use
JP7652823B2 (ja) 腫瘍溶解性ウイルスベクター及びその使用
US20220117902A1 (en) Encapsulated rna polynucleotides and methods of use
JP5652830B2 (ja) マイクロｒｎａ制御組換えワクシニアウイルス及びその使用
KR20180136435A (ko) 종양 살상형 바이러스 벡터 및 그의 용도
US12220456B2 (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
HK40029850A (en) Encapsulated polynucleotides and methods of use
CN119233824A (zh) 编码小核糖核酸病毒的rna多核苷酸的产生
HK40083636B (zh) 用於编码核糖核酸的器官保护性表达和调节的组合物及方法
HK40083636A (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
da Costa MicroRnas as Molecular Targets for Non-Viral Gene Therapy of Glioblastoma: Development of a Lipid-Based Nanosystem for Nucleic Acid Delivery to Brain Tumor Cells

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915